A Study of Talimogene Laherparepvec in Stage IIIc and Stage IV Malignant Melanoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John Nemunaitis, MD
Mary Crowley Medical Research Center
Principal Investigator - Rob Coffin, PhD
BioVex Limited
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Royal Marsden Hospital
London, United Kingdom
- Ucsd Cancer Center, Thornton Hospital
La Jolla, California, United States
- Ucla
Los Angeles, California, United States
- University of Colorado, Anschutz Cancer Pavillion
Aurora, Colorado, United States
- Hubert H Humphrey Cancer Center
Robbinsdale, Minnesota, United States
- Mountainside Hospital
Montclair, New Jersey, United States
- Columbia University, Department of Surgery
New York, New York, United States
- Mary Crowely Medical Research Center
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Dec 2005
- Primary completion
- 31 Dec 2008
- Completion
- 31 May 2009
- Last update posted
- 18 Dec 2015
- Registered enrollment
- 50
- Registry id
- NCT00289016
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.